SGEN - Seagen/Astella announce data showing survival advantage of PADCEV in bladder cancer

Seagen Inc. (SGEN) and Astellas Pharma (ALPMF) announced the interim results from the phase 3 EV-301 trial comparing PADCEV (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer.In the trial involving 600 patients who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor, those who received PADCEV lived a median of 3.9 months longer than those who received chemotherapy.The primary endpoint, median overall survival was 12.9 for PADCEV vs. 9.0 months in chemotherapy. (HR=0.70 [95% Confidence Interval: 0.56-0.89], p=0.001).Median progression-free survival (time without progression of cancer) was 5.6 months for PADCEV vs. 3.7 months for chemotherapy. (HR=0.62 [95% CI: 0.51-0.75]; p<0.00001).Overall response rate (the percentage of patients with either complete or partial response) was 40.6% vs. 17.9% in the chemotherapy arm (p<0.001).Disease control rate (proportion who have achieved a complete response, partial response, or had stable disease) was 71.9% for PADCEV vs 53.4% (p<0.001) in chemotherapy.Suffered by 5%

For further details see:

Seagen/Astella announce data showing survival advantage of PADCEV in bladder cancer